Variable | No-HF (n=159) | HFrEF (n=47) | HFpEF (n=32) | P value |
Unadjusted model | ||||
E-IVPD (mm Hg) | 0.76 (0.68, 0.84) | 0.83 (0.67, 0.98) | 0.83 (0.64, 1.02) | 0.63 |
ER-IVPD (mm Hg) | −0.78 (−0.93, −0.63) | −0.75 (−1.02, −0.47) | −1.30 (−1.60, −0.99) | 0.01*† |
A-IVPD (mm Hg) | 0.93 (0.85, 1.02) | 0.72 (0.56, 0.88) | 0.92 (0.73, 1.11) | 0.07 |
S-IVPD (mm Hg) | 1.7 (1.56, 1.84) | 1.41 (1.16, 1.65) | 1.99 (1.65, 2.34) | 0.01† |
SR-IVPD (mm Hg) | −1.15 (−1.28, −1.02) | −0.90 (−1.17, −0.64) | −1.37 (−1.64, −1.10) | 0.04† |
Adjusted model 1 | ||||
E-IVPD (mm Hg) | 0.75 (0.65, 0.85) | 0.86 (0.64, 1.08) | 0.85 (0.61, 1.08) | 0.70 |
ER-IVPD (mm Hg) | −0.76 (−0.95, −0.56) | −0.85 (−1.23, −0.47) | −1.35 (−1.72, −0.97) | 0.02* |
A-IVPD (mm Hg) | 0.94 (0.83, 1.05) | 0.71 (0.49, 0.92) | 0.94 (0.70, 1.17) | 0.15 |
S-IVPD (mm Hg) | 1.7 (1.52, 1.89) | 1.49 (1.14, 1.84) | 1.89 (1.47, 2.3) | 0.16 |
SR-IVPD (mm Hg) | −1.15 (−1.32, −0.98) | −0.94 (−1.30, −0.58) | −1.34 (−1.67, −1) | 0.14 |
Adjusted model 2 | ||||
E-IVPD (mm Hg) | 0.84 (0.71, 0.97) | 0.93 (0.67, 1.19) | 0.79 (0.54, 1.04) | 0.62 |
ER-IVPD (mm Hg) | −0.68 (−0.92, −0.45) | −0.99 (−1.41, −0.56) | −1.48 (−1.87, −1.08) | 0.009* |
A-IVPD (mm Hg) | 0.97 (0.84, 1.11) | 0.75 (0.50, 1.00) | 0.97 (0.72, 1.22) | 0.27 |
S-IVPD (mm Hg) | 1.72 (1.49, 1.96) | 1.46 (1.03, 1.89) | 1.86 (1.39, 2.33) | 0.25 |
SR-IVPD (mm Hg) | −1.17 (−1.34, −0.99) | −0.83 (−1.21, −0.46) | −1.32 (−1.64, −1.01) | 0.04† |
Adjusted model 3 | ||||
E-IVPD (mm Hg) | 0.85 (0.72, 0.99) | 0.91 (0.63, 1.20) | 0.79 (0.54, 1.05) | 0.76 |
ER-IVPD (mm Hg) | −0.72 (−0.96, −0.49) | −0.87 (−1.34, −0.40) | −1.52 (−1.92, −1.13) | 0.006*† |
A-IVPD (mm Hg) | 0.98 (0.85, 1.12) | 0.73 (0.46, 1.00) | 0.99 (0.73, 1.24) | 0.24 |
S-IVPD (mm Hg) | 1.74 (1.5, 1.98) | 1.47 (1.01, 1.92) | 1.86 (1.37, 2.34) | 0.34 |
SR-IVPD (mm Hg) | −1.17 (−1.35, −0.99) | −0.86 (−1.25, −0.47) | −1.31 (−1.64, −0.99) | 0.11 |
Data are presented as mean (95% CI).
Unadjusted model; adjusted model 1: adjusted for clinical data (age, sex, African American ethnicity, BMI, coronary artery disease, eGFR and beta blocker, ACE-inhibitor, ARB, loop diuretic, and spironolactone use); adjusted model 2: model 1 additionally adjusted for echo parameters (Mitral E-wave velocity, E wave deceleration time, Mitral annular e’ septal); adjusted model 3: model 2 additionally adjusted for MRI data (LV mass index and EDVI).
*p<0.05 for No-HF vs HFpEF.
†p<0.05 for HFrEF vs HFpEF.
‡p<0.05 for No-HF vs HFrEF.
EDVI, end-diastolic volumen index; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; IVPD, intraventricular pressure difference; LV, left ventricular.